Eiger Biopharma licenses Hep C Rx IP from Stanford; TapImmune buys vaccine IP from UBC; Acetylon Pharma closes $7.25M series A to commercialize Dana-Farber, Harvard HDAC inhibitors; EMD Serono and MD Anderson ink clinical trial pact; U of Queensland's IMBcom licenses HGH receptor cell lines to Prolor Biotech
Alnylam will have the exclusive rights to all new inventions resulting from the alliance, as well as the rights to sublicense any related intellectual property. Tekmira will have the right to use new inventions with its own RNAi therapeutics.
The latest pact will focus on the use of p97 as a delivery system to transport Alzheimer's drugs across the blood-brain barrier. Last month, Bioasis and UBC inked a first research collaboration to develop and test a p97-based blood test to diagnose and monitor Alzheimer's.
The research, published online Sunday in Nature Nanotechnology, is the first to show that scientists can detect unlabeled single DNA bases "to a confidence level … appropriate for a highly competitive commercial sequencing system," Oxford Nanopore's CEO said.